128 related articles for article (PubMed ID: 22688249)
1. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin.
Li Y; Zheng X; Cao Z; Xu W; Zhang J; Gong M
Int J Pharm; 2012 Sep; 434(1-2):209-14. PubMed ID: 22688249
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
3. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
4. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA
J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240
[TBL] [Abstract][Full Text] [Related]
6. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
9. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
Herringson TP; Altin JG
J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermia mediated liposomal drug delivery.
Ponce AM; Vujaskovic Z; Yuan F; Needham D; Dewhirst MW
Int J Hyperthermia; 2006 May; 22(3):205-13. PubMed ID: 16754340
[TBL] [Abstract][Full Text] [Related]
11. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
[TBL] [Abstract][Full Text] [Related]
12. Optimisation of vectorisation property: A comparative study for a secondary amphipathic peptide.
Konate K; Lindberg MF; Vaissiere A; Jourdan C; Aldrian G; Margeat E; Deshayes S; Boisguerin P
Int J Pharm; 2016 Jul; 509(1-2):71-84. PubMed ID: 27224007
[TBL] [Abstract][Full Text] [Related]
13. Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles.
Rydström A; Deshayes S; Konate K; Crombez L; Padari K; Boukhaddaoui H; Aldrian G; Pooga M; Divita G
PLoS One; 2011; 6(10):e25924. PubMed ID: 21998722
[TBL] [Abstract][Full Text] [Related]
14. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors.
Mayer LD; Dougherty G; Harasym TO; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1406-14. PubMed ID: 9067330
[TBL] [Abstract][Full Text] [Related]
15. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells.
Kurzawa L; Pellerano M; Morris MC
Biochim Biophys Acta; 2010 Dec; 1798(12):2274-85. PubMed ID: 20188697
[TBL] [Abstract][Full Text] [Related]
16. Novel tetrapeptide, RGDF, mediated tumor specific liposomal doxorubicin (DOX) preparations.
Du H; Cui C; Wang L; Liu H; Cui G
Mol Pharm; 2011 Aug; 8(4):1224-32. PubMed ID: 21630705
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
18. Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells.
Morisco A; Accardo A; Tesauro D; Palumbo R; Benedetti E; Morelli G
Biopolymers; 2011; 96(1):88-96. PubMed ID: 20560147
[TBL] [Abstract][Full Text] [Related]
19. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
20. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
